Phacilitate Leaders World

Speakers

Loading
Mark Zimmerman

Mark Zimmerman

, Vice President, Strategy and Business Development, Interim Vice President of Operations, Viacyte

Mark C. Zimmerman, Ph.D., a leader in diabetes and regenerative medicine for over two decades, is responsible for strategy and business development and is the interim Vice President of Operations.  He is seconded to ViaCyte, after Johnson and Johnson completed a business transaction with ViaCyte and merged the assets of BetaLogics, a business unit of Janssen R&D LLC, into ViaCyte.  The mission of BetaLogics was to discover and develop a cellular product to treat diabetes.  Dr. Zimmerman was appointed Executive Director of BetaLogics in 2002, and Venture Leader/Vice President of BetaLogics in 2009.  Before the establishment of BetaLogics, Dr. Zimmerman was a Principal Scientist and Group Leader at Johnson and Johnson heading up regenerative medicine projects related to orthopedic surgery, wound healing, vascular biology, and diabetes.  Prior to Johnson and Johnson, Dr. Zimmerman was an Associate Professor of Surgery at UMD-New Jersey Medical School.  Dr. Zimmerman received his B.S. in Biology from Syracuse University and his M.S. and Ph.D. in Biomedical Engineering from Rutgers University. 

 

Sessions
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK